218 related articles for article (PubMed ID: 28013483)
41. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
Rodriguez R; Parker P; Nademanee A; Smith D; O'Donnell MR; Stein A; Snyder DS; Fung HC; Krishnan AY; Popplewell L; Cohen S; Somlo G; Angelopoulou M; Al-Kadhimi Z; Falk PM; Spielberger R; Kogut N; Sahebi F; Senitzer D; Slovak M; Schriber J; Forman SJ
Bone Marrow Transplant; 2004 Jun; 33(11):1123-9. PubMed ID: 15064696
[TBL] [Abstract][Full Text] [Related]
42. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
Saure C; Schroeder T; Zohren F; Groten A; Bruns I; Czibere A; Galonska L; Kondakci M; Weigelt C; Fenk R; Germing U; Haas R; Kobbe G
Biol Blood Marrow Transplant; 2012 Mar; 18(3):466-72. PubMed ID: 21963618
[TBL] [Abstract][Full Text] [Related]
43. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
44. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Cho BS; Lee S; Kim YJ; Chung NG; Eom KS; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
Leukemia; 2009 Oct; 23(10):1763-70. PubMed ID: 19440217
[TBL] [Abstract][Full Text] [Related]
45. Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Schlenk RF; Hartmann F; Hensel M; Jung W; Weber-Nordt R; Gabler A; Haas R; Ho AD; Trümper L; Döhner H
Leukemia; 2002 Apr; 16(4):581-6. PubMed ID: 11960336
[TBL] [Abstract][Full Text] [Related]
46. [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].
Wang FR; Huang XJ; Liu DH; Chen H; Wang Y; Tang FF; Sun YQ; Fu HX; Liu KY; Xu LP
Zhonghua Nei Ke Za Zhi; 2013 Dec; 52(12):1028-32. PubMed ID: 24503400
[TBL] [Abstract][Full Text] [Related]
47. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
48. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit anti-thymocyte globulin.
Horan JT; Liesveld JL; Fenton P; Blumberg N; Walters MC
Bone Marrow Transplant; 2005 Jan; 35(2):171-7. PubMed ID: 15531901
[TBL] [Abstract][Full Text] [Related]
49. Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.
Hannon M; Beguin Y; Ehx G; Servais S; Seidel L; Graux C; Maertens J; Kerre T; Daulne C; de Bock M; Fillet M; Ory A; Willems E; Gothot A; Humblet-Baron S; Baron F
Clin Cancer Res; 2015 Jul; 21(14):3131-9. PubMed ID: 25779951
[TBL] [Abstract][Full Text] [Related]
50. Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.
Hoshino T; Takada S; Hatsumi N; Sakura T
Int J Hematol; 2019 Apr; 109(4):463-469. PubMed ID: 30734904
[TBL] [Abstract][Full Text] [Related]
51. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
[TBL] [Abstract][Full Text] [Related]
52. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
53. Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation.
Srinivasan R; Takahashi Y; McCoy JP; Espinoza-Delgado I; Dorrance C; Igarashi T; Lundqvist A; Barrett AJ; Young NS; Geller N; Childs RW
Br J Haematol; 2006 May; 133(3):305-14. PubMed ID: 16643433
[TBL] [Abstract][Full Text] [Related]
54. Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Hamaki T; Kami M; Kim SW; Onishi Y; Kishi Y; Murashige N; Hori A; Kojima R; Sakiyama M; Imataki O; Heike Y; Tanosaki R; Masuo S; Miyakoshi S; Taniguchi S; Tobinai K; Takaue Y
Bone Marrow Transplant; 2004 May; 33(9):891-900. PubMed ID: 15048142
[TBL] [Abstract][Full Text] [Related]
55. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
56. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuk F; Diyachenko G; Zabelina T; Panse J; Wolschke C; Eiermann T; Binder T; Fehse B; Erttmann R; Kabisch H; Bacher U; Kröger N; Zander AR
Exp Hematol; 2008 Aug; 36(8):1047-54. PubMed ID: 18456390
[TBL] [Abstract][Full Text] [Related]
57. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
58. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study.
Hamidieh AA; Behfar M; Pourpak Z; Faghihi-Kashani S; Fazlollahi MR; Hosseini AS; Movahedi M; Mozafari M; Moin M; Ghavamzadeh A
Bone Marrow Transplant; 2016 Feb; 51(2):219-26. PubMed ID: 26595073
[TBL] [Abstract][Full Text] [Related]
59. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
60. Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia.
Fu H; Xu L; Liu D; Liu K; Zhang X; Chen H; Chen Y; Han W; Wang Y; Wang J; Wang F; Huang X
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1176-82. PubMed ID: 24747336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
